111 related articles for article (PubMed ID: 12899128)
21. Effects of a typical I(Kr) channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes.
Sugiyama A; Hashimoto K
Jpn J Pharmacol; 2002 Apr; 88(4):414-21. PubMed ID: 12046984
[TBL] [Abstract][Full Text] [Related]
22. [Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Sugiyama A
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):393-400. PubMed ID: 12835533
[TBL] [Abstract][Full Text] [Related]
23. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
24. hERG: protein trafficking and potential for therapy and drug side effects.
Staudacher I; Schweizer PA; Katus HA; Thomas D
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
[TBL] [Abstract][Full Text] [Related]
25. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Cavalli A; Poluzzi E; De Ponti F; Recanatini M
J Med Chem; 2002 Aug; 45(18):3844-53. PubMed ID: 12190308
[TBL] [Abstract][Full Text] [Related]
26. [QTc-prolongation in acute drug-poisoning. Guidelines for management from the Swedish Poisons Information Centre].
Höjer J
Lakartidningen; 2013 May 7-21; 110(19-20):953-5. PubMed ID: 23745503
[No Abstract] [Full Text] [Related]
27. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.
Testai L; Bianucci AM; Massarelli I; Breschi MC; Martinotti E; Calderone V
Curr Med Chem; 2004 Oct; 11(20):2691-706. PubMed ID: 15544470
[TBL] [Abstract][Full Text] [Related]
28. Genetic modulation of cardiac repolarization reserve.
Remme CA; Bezzina CR
Heart Rhythm; 2007 May; 4(5):608-10. PubMed ID: 17467629
[No Abstract] [Full Text] [Related]
29. Quetiapine and the need for a thorough QT/QTc study.
Hasnain M; Vieweg WV; Howland RH; Kogut C; Breden Crouse EL; Koneru JN; Hancox JC; Digby GC; Baranchuk A; Deshmukh A; Pandurangi AK
J Clin Psychopharmacol; 2014 Feb; 34(1):3-6. PubMed ID: 24346758
[No Abstract] [Full Text] [Related]
30. Detection of drug-induced proarrhythmia: balancing preclinical and clinical studies.
Malik M
Heart Rhythm; 2005 Jul; 2(7):773-6. PubMed ID: 15992737
[No Abstract] [Full Text] [Related]
31. Drug-induced QT prolongation: consequences and current dilemma.
Dubrey SW; Grocott-Mason R
Br J Hosp Med (Lond); 2007 Jan; 68(1):50-1. PubMed ID: 17260721
[No Abstract] [Full Text] [Related]
32. Drug-induced long QT syndrome: a continuing challenge in the field.
Glatter KA; Hamdan MH; Zhang Q; Chiamvimonvat N
J Cardiovasc Electrophysiol; 2007 Jul; 18(7):696-7. PubMed ID: 17537200
[No Abstract] [Full Text] [Related]
33. Drug induced QT prolongation: lessons from congenital and acquired long QT syndromes.
Walker BD; Krahn AD; Klein GJ; Skanes AC; Yee R
Curr Drug Targets Cardiovasc Haematol Disord; 2003 Dec; 3(4):327-35. PubMed ID: 14683474
[TBL] [Abstract][Full Text] [Related]
34. Drug induced QT prolongation and torsades de pointes.
Yap YG; Camm AJ
Heart; 2003 Nov; 89(11):1363-72. PubMed ID: 14594906
[No Abstract] [Full Text] [Related]
35. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.
Titier K; Girodet PO; Verdoux H; Molimard M; Bégaud B; Haverkamp W; Lader M; Moore N
Drug Saf; 2005; 28(1):35-51. PubMed ID: 15649104
[TBL] [Abstract][Full Text] [Related]
36. Improving the assessment of heart toxicity for all new drugs through translational regulatory science.
Johannesen L; Vicente J; Gray RA; Galeotti L; Loring Z; Garnett CE; Florian J; Ugander M; Stockbridge N; Strauss DG
Clin Pharmacol Ther; 2014 May; 95(5):501-8. PubMed ID: 24336137
[TBL] [Abstract][Full Text] [Related]
37. QT interval prolongation: and the beat goes on.
Jalaie M; Holsworth DD
Mini Rev Med Chem; 2005 Dec; 5(12):1083-91. PubMed ID: 16375754
[TBL] [Abstract][Full Text] [Related]
38. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes.
Kääb S; Crawford DC; Sinner MF; Behr ER; Kannankeril PJ; Wilde AA; Bezzina CR; Schulze-Bahr E; Guicheney P; Bishopric NH; Myerburg RJ; Schott JJ; Pfeufer A; Beckmann BM; Martens E; Zhang T; Stallmeyer B; Zumhagen S; Denjoy I; Bardai A; Van Gelder IC; Jamshidi Y; Dalageorgou C; Marshall V; Jeffery S; Shakir S; Camm AJ; Steinbeck G; Perz S; Lichtner P; Meitinger T; Peters A; Wichmann HE; Ingram C; Bradford Y; Carter S; Norris K; Ritchie MD; George AL; Roden DM
Circ Cardiovasc Genet; 2012 Feb; 5(1):91-9. PubMed ID: 22100668
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced changes in the T-wave morphology.
Malik M
Drug Saf; 2009; 32(7):613-7. PubMed ID: 19530747
[No Abstract] [Full Text] [Related]
40. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays.
Wallis RM
Br J Pharmacol; 2010 Jan; 159(1):115-21. PubMed ID: 19785646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
